The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1 study in obese or overweight individuals; top-line ...